Shopping Cart 0
Cart Subtotal
AED 0

Latin America Point of Care Infectious Disease Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 15414

Details

Latin America point of care infectious disease market is projected to register a CAGR of 8.3% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Latin America Point of Care Infectious Disease Market By Type (Products and Services), Technology (Immunodiagnostics, Molecular Diagnostics, Dipsticks, Microfluidics and Others), Application (Tropical Diseases, Sexually Transmitted Disease, Respiratory Disorders, Liver Disorders, Inflammatory Diseases, Hospital Acquired Infections (HAIS), GI Infections, CNS Infections, Cardiovascular Infection and Others), Availability (Over-the-Counter (OTC) Testing Kits and Prescription-Based Testing Kits), End Users (Homecare Setting, Hospitals, Diagnostic Centers, Outpatient Healthcare Setting and Others),Distribution Channel (Direct Tenders and Retail Sales) Country ( Brazil, Mexico, Chile, Equador, Colombia, Argentina, Peru and Rest Of Latin America), Market Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Latin America point of care infectious disease market are:

Increasing prevalence of infectious diseases

Need for reduction of antibiotic misuse

Technological advancements in POCT devices

Market Players:

The key market players for Latin America point of care infectious disease market are listed below:

Abbott

BD

BioMerieux SA

F. Hoffmann-La Roche Ltd

Siemens Healthineers AG

Chembio Diagnostic Systems, Inc.

Cardinal health

Koninklijke Philips N.V.

Thermo Fisher Scientific, Inc.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15

1.2 MARKET DEFINITION 15

1.3 OVERVIEW OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET 19

1.4 LIMITATIONS 20

1.5 MARKETS COVERED 20

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22

2.2 GEOGRAPHICAL SCOPE 23

2.3 YEARS CONSIDERED FOR THE STUDY 24

2.4 CURRENCY AND PRICING 24

2.5 DBMR TRIPOD DATA VALIDATION MODEL 25

2.6 MULTIVARIATE MODELLING 28

2.7 TYPE LIFELINE CURVE 28

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29

2.9 MARKET APPLICATION COVERAGE GRID 30

2.10 DBMR MARKET POSITION GRID 31

2.11 VENDOR SHARE ANALYSIS 32

2.12 SECONDARY SOURCES 33

2.13 ASSUMPTIONS 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 36

5 MARKET OVERVIEW 37

5.1 DRIVERS 39

5.1.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES 39

5.1.2 NEED FOR REDUCTION OF ANTIBIOTIC MISUSE 40

5.1.3 TECHNOLOGICAL ADVANCEMENTS IN POCT DEVICES 41

5.1.4 HIGH USAGE OF POCT DEVICES IN HOMECARE SETTINGS 42

5.1.5 INCLINATION TOWARDS EARLY AND QUICK DIAGNOSIS 42

5.2 RESTRAINTS 43

5.2.1 STRINGENT REGULATORY LANDSCAPE 43

5.2.2 UNFAVOURABLE REIMBURSEMENT SCENARIO 44

5.2.3 LACK OF AWARENESS REGARDING AVAILABILITY OF PRODUCTS 44

5.3 OPPORTUNITIES 45

5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES 45

5.3.2 GROWING ACCEPTANCE OF COMPANION DIAGNOSTICS IN VARIOUS APPLICATIONS 45

5.4 CHALLENGES 46

5.4.1 RELUCTANCE TOWARDS CHANGING EXISTING DIAGNOSTIC PRACTICES 46

5.4.2 HIGH COST OF POCT AS COMPARED TO TRADITIONAL METHODS 47

6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE 48

6.1 OVERVIEW 49

6.2 PRODUCTS 51

6.2.1 REAGENTS & KITS 51

6.2.1.1 HEMATOLOGY TESTING KITS 51

6.2.1.2 URINALYSIS TESTING KITS 52

6.2.1.3 INFLUENZA TESTING KITS 52

6.2.1.4 STD TESTING KITS 52

6.2.1.5 HIV TESTING KITS 52

6.2.1.6 OTHERS 52

6.2.2 EQUIPMENT 52

6.2.2.1 ANALYZERS 53

6.2.2.2 CONTAINERS 53

6.2.2.3 BAGS 53

6.2.2.4 COLLECTION TUBES 53

6.2.2.5 OTHERS 53

6.2.3 BIOMARKERS 53

6.2.3.1 BACTERIA 53

6.2.3.2 VIRUS 54

6.2.3.3 PARASITES 54

6.2.3.4 FUNGI 54

6.2.4 OTHERS 54

6.3 SERVICES 54

7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY 55

7.1 OVERVIEW 56

7.2 IMMUNODIAGNOSTICS 58

7.2.1 RAPID TEST 58

7.2.2 ELISA 58

7.2.3 OTHERS 58

7.3 MOLECULAR DIAGNOSTICS 58

7.4 DIPSTICKS 58

7.5 MICROFLUIDICS 59

7.6 OTHERS 59

8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION 60

8.1 OVERVIEW 61

8.2 TROPICAL DISEASES 63

8.3 SEXUALLY TRANSMITTED DISEASE 63

8.4 RESPIRATORY DISORDERS 63

8.5 LIVER DISORDERS 63

8.6 INFLAMMATORY DISEASES 63

8.7 HOSPITAL ACQUIRED INFECTIONS (HAIS) 64

8.8 GI INFECTIONS 64

8.9 CNS INFECTIONS 64

8.10 CARDIOVASCULAR INFECTION 64

8.11 OTHERS 64

9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY 65

9.1 OVERVIEW 66

9.2 OVER-THE-COUNTER (OTC) TESTING KITS 68

9.3 PRESCRIPTION-BASED TESTING KITS 68

10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS 69

10.1 OVERVIEW 70

10.2 HOSPITALS 72

10.3 OUTPATIENT HEALTHCARE SETTING 72

10.4 HOMECARE SETTING 72

10.5 OTHERS 72

11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL 73

11.1 OVERVIEW 74

11.2 DIRECT TENDERS 76

11.3 RETAIL SALES 76

12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY 77

12.1 BRAZIL 82

12.2 MEXICO 86

12.3 ARGENTINA 90

12.4 COLOMBIA 94

12.5 CHILE 98

12.6 PERU 102

12.7 ECUADOR 106

12.8 REST OF LATIN AMERICA 110

13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, COMPANY LANDSCAPE 111

14 SWOT ANALYSIS 112

14.1 STRENGTH:-112

14.1.1 SIGNIFICANT INCREASING SHARES IN MARKET FOCUSED SEGMENT 112

14.1.2 STRONG GLOBAL PRESENCE 112

14.2 WEAKNESS:-LOW R&D INVESTMENTS 113

14.3 OPPORTUNITY:-INITIATIVES FOR EXPANDING BUSINESS 113

14.3.1 THREAT:-CURRENCY CONVERSION 114

14.4 DATA BRIDGE MARKET RESEARCH ANALYSIS 114

15 CONCLUSION 115

16 QUESTIONNAIRE 116

17 RELATED REPORTS 119


List Of Figure

LIST OF FIGURES

FIGURE 1 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION 22

FIGURE 2 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 25

FIGURE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DROC ANALYSIS 26

FIGURE 4 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS 27

FIGURE 5 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : COMPANY RESEARCH ANALYSIS 27

FIGURE 6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 29

FIGURE 7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 30

FIGURE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 31

FIGURE 9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE : VENDOR SHARE ANALYSIS 32

FIGURE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION 35

FIGURE 11 INCREASING PREVALENCE OF INFECTIOUS DISEASE AND NEED FOR REDUCTION OF ANTIBIOTIC USE ARE DRIVING THE LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 36

FIGURE 12 PRODUCTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN 2020 & 2027 36

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET 38

FIGURE 14 GENERAL PROCESS OF MEDICAL DEVICE REGULATION BY THE FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK (COFEPRIS) IN MEXICO 43

FIGURE 15 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019 49

FIGURE 16 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019-2027 (USD MILLION) 49

FIGURE 17 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, CAGR (2020-2027) 50

FIGURE 18 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, LIFELINE CURVE 50

FIGURE 19 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019 56

FIGURE 20 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019-2027 (USD MILLION) 56

FIGURE 21 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, CAGR (2020-2027) 57

FIGURE 22 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, LIFELINE CURVE 57

FIGURE 23 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019 61

FIGURE 24 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019-2027 (USD MILLION) 61

FIGURE 25 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, CAGR (2020-2027) 62

FIGURE 26 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, LIFELINE CURVE 62

FIGURE 27 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019 66

FIGURE 28 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019-2027 (USD MILLION) 66

FIGURE 29 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, CAGR (2020-2027) 67

FIGURE 30 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, LIFELINE CURVE 67

FIGURE 31 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019 70

FIGURE 32 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019-2027 (USD MILLION) 70

FIGURE 33 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, CAGR (2020-2027) 71

FIGURE 34 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, LIFELINE CURVE 71

FIGURE 35 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019 74

FIGURE 36 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 74

FIGURE 37 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL CAGR (2020-2027) 75

FIGURE 38 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 75

FIGURE 39 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SNAPSHOT (2019) 78

FIGURE 40 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019) 79

FIGURE 41 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2020 & 2027) 79

FIGURE 42 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019 & 2027) 80

FIGURE 43 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE (2020-2027) 80

FIGURE 44 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: COMPANY SHARE 2019 (%) 111


List Of Table

LIST OF TABLES

UU

TABLE 1 MULTIPLEXING PLATFORMS MANUFATURED BY DIFFERENT COMPANIES FOR DETECTION OF INFECTIOUS DISEASES 45

TABLE 2 TEST COSTS (USD) BY TEST PROCEDURE AND TESTING REGIME 47

TABLE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 50

TABLE 4 LATIN AMERICA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 51

TABLE 5 LATIN AMERICA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 51

TABLE 6 LATIN AMERICA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 52

TABLE 7 LATIN AMERICA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 53

TABLE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USER, 2018-2027 (USD MILLION) 57

TABLE 9 LATIN AMERICA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 58

TABLE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 63

TABLE 11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 67

TABLE 12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 71

TABLE 13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 75

TABLE 14 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY, 2018-2027 (USD MILLION) 81

TABLE 15 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 16 BRAZIL PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 17 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 18 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 83

TABLE 19 BRAZIL EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 83

TABLE 20 BRAZIL BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 83

TABLE 21 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 84

TABLE 22 BRAZIL IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 84

TABLE 23 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 84

TABLE 24 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 85

TABLE 25 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 85

TABLE 26 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 85

TABLE 27 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 28 MEXICO PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 29 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 30 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 87

TABLE 31 MEXICO EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 87

TABLE 32 MEXICO BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 87

TABLE 33 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 88

TABLE 34 MEXICO IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 88

TABLE 35 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 88

TABLE 36 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 89

TABLE 37 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 89

TABLE 38 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 89

TABLE 39 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 40 ARGENTINA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 41 ARGENTINA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 42 ARGENTNA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 91

TABLE 43 ARGENTINA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 91

TABLE 44 ARGENTINA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 91

TABLE 45 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 92

TABLE 46 ARGENTINA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 92

TABLE 47 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 92

TABLE 48 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 93

TABLE 49 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 93

TABLE 50 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 93

TABLE 51 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 52 COLOMBIA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 53 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 54 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 95

TABLE 55 COLOMBIA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 95

TABLE 56 COLOMBIA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 95

TABLE 57 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 96

TABLE 58 COLOMBIA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 96

TABLE 59 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 96

TABLE 60 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 97

TABLE 61 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 97

TABLE 62 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 97

TABLE 63 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 64 CHILE PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 65 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 66 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 99

TABLE 67 CHILE EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 99

TABLE 68 CHILE BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 99

TABLE 69 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 100

TABLE 70 CHILE IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 100

TABLE 71 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 100

TABLE 72 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 101

TABLE 73 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 101

TABLE 74 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 101

TABLE 75 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 76 PERU PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 77 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 78 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 103

TABLE 79 PERU EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 103

TABLE 80 PERU BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 103

TABLE 81 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 104

TABLE 82 PERU IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 104

TABLE 83 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 104

TABLE 84 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 105

TABLE 85 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 105

TABLE 86 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 105

TABLE 87 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 88 ECUADOR PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 89 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 90 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 107

TABLE 91 ECUADOR EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 107

TABLE 92 ECUADOR BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 107

TABLE 93 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 108

TABLE 94 ECUADOR IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 108

TABLE 95 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 108

TABLE 96 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 109

TABLE 97 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 109

TABLE 98 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 109

TABLE 99 REST OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 110

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Abbott

BD

BioMerieux SA

F. Hoffmann-La Roche Ltd

Siemens Healthineers AG

Chembio Diagnostic Systems, Inc.

Cardinal health

Koninklijke Philips N.V.

Thermo Fisher Scientific, Inc.

Company Profile

Company Profile Title

Latin America point of care infectious disease market is projected to register a CAGR of 8.3% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Latin America Point of Care Infectious Disease Market By Type (Products and Services), Technology (Immunodiagnostics, Molecular Diagnostics, Dipsticks, Microfluidics and Others), Application (Tropical Diseases, Sexually Transmitted Disease, Respiratory Disorders, Liver Disorders, Inflammatory Diseases, Hospital Acquired Infections (HAIS), GI Infections, CNS Infections, Cardiovascular Infection and Others), Availability (Over-the-Counter (OTC) Testing Kits and Prescription-Based Testing Kits), End Users (Homecare Setting, Hospitals, Diagnostic Centers, Outpatient Healthcare Setting and Others),Distribution Channel (Direct Tenders and Retail Sales) Country ( Brazil, Mexico, Chile, Equador, Colombia, Argentina, Peru and Rest Of Latin America), Market Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Latin America point of care infectious disease market are:

Increasing prevalence of infectious diseases

Need for reduction of antibiotic misuse

Technological advancements in POCT devices

Market Players:

The key market players for Latin America point of care infectious disease market are listed below:

Abbott

BD

BioMerieux SA

F. Hoffmann-La Roche Ltd

Siemens Healthineers AG

Chembio Diagnostic Systems, Inc.

Cardinal health

Koninklijke Philips N.V.

Thermo Fisher Scientific, Inc.

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15

1.2 MARKET DEFINITION 15

1.3 OVERVIEW OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET 19

1.4 LIMITATIONS 20

1.5 MARKETS COVERED 20

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22

2.2 GEOGRAPHICAL SCOPE 23

2.3 YEARS CONSIDERED FOR THE STUDY 24

2.4 CURRENCY AND PRICING 24

2.5 DBMR TRIPOD DATA VALIDATION MODEL 25

2.6 MULTIVARIATE MODELLING 28

2.7 TYPE LIFELINE CURVE 28

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29

2.9 MARKET APPLICATION COVERAGE GRID 30

2.10 DBMR MARKET POSITION GRID 31

2.11 VENDOR SHARE ANALYSIS 32

2.12 SECONDARY SOURCES 33

2.13 ASSUMPTIONS 33

3 EXECUTIVE SUMMARY 34

4 PREMIUM INSIGHTS 36

5 MARKET OVERVIEW 37

5.1 DRIVERS 39

5.1.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES 39

5.1.2 NEED FOR REDUCTION OF ANTIBIOTIC MISUSE 40

5.1.3 TECHNOLOGICAL ADVANCEMENTS IN POCT DEVICES 41

5.1.4 HIGH USAGE OF POCT DEVICES IN HOMECARE SETTINGS 42

5.1.5 INCLINATION TOWARDS EARLY AND QUICK DIAGNOSIS 42

5.2 RESTRAINTS 43

5.2.1 STRINGENT REGULATORY LANDSCAPE 43

5.2.2 UNFAVOURABLE REIMBURSEMENT SCENARIO 44

5.2.3 LACK OF AWARENESS REGARDING AVAILABILITY OF PRODUCTS 44

5.3 OPPORTUNITIES 45

5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES 45

5.3.2 GROWING ACCEPTANCE OF COMPANION DIAGNOSTICS IN VARIOUS APPLICATIONS 45

5.4 CHALLENGES 46

5.4.1 RELUCTANCE TOWARDS CHANGING EXISTING DIAGNOSTIC PRACTICES 46

5.4.2 HIGH COST OF POCT AS COMPARED TO TRADITIONAL METHODS 47

6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE 48

6.1 OVERVIEW 49

6.2 PRODUCTS 51

6.2.1 REAGENTS & KITS 51

6.2.1.1 HEMATOLOGY TESTING KITS 51

6.2.1.2 URINALYSIS TESTING KITS 52

6.2.1.3 INFLUENZA TESTING KITS 52

6.2.1.4 STD TESTING KITS 52

6.2.1.5 HIV TESTING KITS 52

6.2.1.6 OTHERS 52

6.2.2 EQUIPMENT 52

6.2.2.1 ANALYZERS 53

6.2.2.2 CONTAINERS 53

6.2.2.3 BAGS 53

6.2.2.4 COLLECTION TUBES 53

6.2.2.5 OTHERS 53

6.2.3 BIOMARKERS 53

6.2.3.1 BACTERIA 53

6.2.3.2 VIRUS 54

6.2.3.3 PARASITES 54

6.2.3.4 FUNGI 54

6.2.4 OTHERS 54

6.3 SERVICES 54

7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY 55

7.1 OVERVIEW 56

7.2 IMMUNODIAGNOSTICS 58

7.2.1 RAPID TEST 58

7.2.2 ELISA 58

7.2.3 OTHERS 58

7.3 MOLECULAR DIAGNOSTICS 58

7.4 DIPSTICKS 58

7.5 MICROFLUIDICS 59

7.6 OTHERS 59

8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION 60

8.1 OVERVIEW 61

8.2 TROPICAL DISEASES 63

8.3 SEXUALLY TRANSMITTED DISEASE 63

8.4 RESPIRATORY DISORDERS 63

8.5 LIVER DISORDERS 63

8.6 INFLAMMATORY DISEASES 63

8.7 HOSPITAL ACQUIRED INFECTIONS (HAIS) 64

8.8 GI INFECTIONS 64

8.9 CNS INFECTIONS 64

8.10 CARDIOVASCULAR INFECTION 64

8.11 OTHERS 64

9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY 65

9.1 OVERVIEW 66

9.2 OVER-THE-COUNTER (OTC) TESTING KITS 68

9.3 PRESCRIPTION-BASED TESTING KITS 68

10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS 69

10.1 OVERVIEW 70

10.2 HOSPITALS 72

10.3 OUTPATIENT HEALTHCARE SETTING 72

10.4 HOMECARE SETTING 72

10.5 OTHERS 72

11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL 73

11.1 OVERVIEW 74

11.2 DIRECT TENDERS 76

11.3 RETAIL SALES 76

12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY 77

12.1 BRAZIL 82

12.2 MEXICO 86

12.3 ARGENTINA 90

12.4 COLOMBIA 94

12.5 CHILE 98

12.6 PERU 102

12.7 ECUADOR 106

12.8 REST OF LATIN AMERICA 110

13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, COMPANY LANDSCAPE 111

14 SWOT ANALYSIS 112

14.1 STRENGTH:-112

14.1.1 SIGNIFICANT INCREASING SHARES IN MARKET FOCUSED SEGMENT 112

14.1.2 STRONG GLOBAL PRESENCE 112

14.2 WEAKNESS:-LOW R&D INVESTMENTS 113

14.3 OPPORTUNITY:-INITIATIVES FOR EXPANDING BUSINESS 113

14.3.1 THREAT:-CURRENCY CONVERSION 114

14.4 DATA BRIDGE MARKET RESEARCH ANALYSIS 114

15 CONCLUSION 115

16 QUESTIONNAIRE 116

17 RELATED REPORTS 119


List Of Figure

LIST OF FIGURES

FIGURE 1 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION 22

FIGURE 2 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 25

FIGURE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DROC ANALYSIS 26

FIGURE 4 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS 27

FIGURE 5 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : COMPANY RESEARCH ANALYSIS 27

FIGURE 6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 29

FIGURE 7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 30

FIGURE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 31

FIGURE 9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE : VENDOR SHARE ANALYSIS 32

FIGURE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION 35

FIGURE 11 INCREASING PREVALENCE OF INFECTIOUS DISEASE AND NEED FOR REDUCTION OF ANTIBIOTIC USE ARE DRIVING THE LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 36

FIGURE 12 PRODUCTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN 2020 & 2027 36

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET 38

FIGURE 14 GENERAL PROCESS OF MEDICAL DEVICE REGULATION BY THE FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK (COFEPRIS) IN MEXICO 43

FIGURE 15 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019 49

FIGURE 16 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019-2027 (USD MILLION) 49

FIGURE 17 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, CAGR (2020-2027) 50

FIGURE 18 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, LIFELINE CURVE 50

FIGURE 19 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019 56

FIGURE 20 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019-2027 (USD MILLION) 56

FIGURE 21 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, CAGR (2020-2027) 57

FIGURE 22 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, LIFELINE CURVE 57

FIGURE 23 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019 61

FIGURE 24 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019-2027 (USD MILLION) 61

FIGURE 25 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, CAGR (2020-2027) 62

FIGURE 26 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, LIFELINE CURVE 62

FIGURE 27 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019 66

FIGURE 28 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019-2027 (USD MILLION) 66

FIGURE 29 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, CAGR (2020-2027) 67

FIGURE 30 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, LIFELINE CURVE 67

FIGURE 31 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019 70

FIGURE 32 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019-2027 (USD MILLION) 70

FIGURE 33 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, CAGR (2020-2027) 71

FIGURE 34 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, LIFELINE CURVE 71

FIGURE 35 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019 74

FIGURE 36 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION) 74

FIGURE 37 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL CAGR (2020-2027) 75

FIGURE 38 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 75

FIGURE 39 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SNAPSHOT (2019) 78

FIGURE 40 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019) 79

FIGURE 41 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2020 & 2027) 79

FIGURE 42 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019 & 2027) 80

FIGURE 43 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE (2020-2027) 80

FIGURE 44 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: COMPANY SHARE 2019 (%) 111


List Of Table

LIST OF TABLES

UU

TABLE 1 MULTIPLEXING PLATFORMS MANUFATURED BY DIFFERENT COMPANIES FOR DETECTION OF INFECTIOUS DISEASES 45

TABLE 2 TEST COSTS (USD) BY TEST PROCEDURE AND TESTING REGIME 47

TABLE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 50

TABLE 4 LATIN AMERICA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 51

TABLE 5 LATIN AMERICA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 51

TABLE 6 LATIN AMERICA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 52

TABLE 7 LATIN AMERICA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 53

TABLE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USER, 2018-2027 (USD MILLION) 57

TABLE 9 LATIN AMERICA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 58

TABLE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 63

TABLE 11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 67

TABLE 12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 71

TABLE 13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 75

TABLE 14 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY, 2018-2027 (USD MILLION) 81

TABLE 15 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 16 BRAZIL PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 17 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 82

TABLE 18 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 83

TABLE 19 BRAZIL EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 83

TABLE 20 BRAZIL BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 83

TABLE 21 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 84

TABLE 22 BRAZIL IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 84

TABLE 23 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 84

TABLE 24 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 85

TABLE 25 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 85

TABLE 26 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 85

TABLE 27 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 28 MEXICO PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 29 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 86

TABLE 30 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 87

TABLE 31 MEXICO EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 87

TABLE 32 MEXICO BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 87

TABLE 33 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 88

TABLE 34 MEXICO IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 88

TABLE 35 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 88

TABLE 36 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 89

TABLE 37 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 89

TABLE 38 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 89

TABLE 39 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 40 ARGENTINA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 41 ARGENTINA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 90

TABLE 42 ARGENTNA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 91

TABLE 43 ARGENTINA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 91

TABLE 44 ARGENTINA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 91

TABLE 45 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 92

TABLE 46 ARGENTINA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 92

TABLE 47 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 92

TABLE 48 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 93

TABLE 49 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 93

TABLE 50 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 93

TABLE 51 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 52 COLOMBIA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 53 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 94

TABLE 54 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 95

TABLE 55 COLOMBIA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 95

TABLE 56 COLOMBIA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 95

TABLE 57 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 96

TABLE 58 COLOMBIA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 96

TABLE 59 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 96

TABLE 60 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 97

TABLE 61 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 97

TABLE 62 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 97

TABLE 63 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 64 CHILE PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 65 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 98

TABLE 66 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 99

TABLE 67 CHILE EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 99

TABLE 68 CHILE BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 99

TABLE 69 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 100

TABLE 70 CHILE IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 100

TABLE 71 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 100

TABLE 72 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 101

TABLE 73 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 101

TABLE 74 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 101

TABLE 75 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 76 PERU PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 77 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 102

TABLE 78 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 103

TABLE 79 PERU EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 103

TABLE 80 PERU BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 103

TABLE 81 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 104

TABLE 82 PERU IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 104

TABLE 83 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 104

TABLE 84 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 105

TABLE 85 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 105

TABLE 86 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 105

TABLE 87 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 88 ECUADOR PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 89 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 106

TABLE 90 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS) 107

TABLE 91 ECUADOR EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 107

TABLE 92 ECUADOR BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 107

TABLE 93 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 108

TABLE 94 ECUADOR IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION) 108

TABLE 95 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION) 108

TABLE 96 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION) 109

TABLE 97 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION) 109

TABLE 98 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 109

TABLE 99 REST OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION) 110

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Abbott

BD

BioMerieux SA

F. Hoffmann-La Roche Ltd

Siemens Healthineers AG

Chembio Diagnostic Systems, Inc.

Cardinal health

Koninklijke Philips N.V.

Thermo Fisher Scientific, Inc.